AMP Agency Acquires Genome

Genome Medical Acquires GeneMatters

August 30, 2021

Healthcare Services

Genome Medical, a South San Francisco–based genomic care delivery company, will acquire GeneMatters, a telehealth genetic counseling and software solutions provider. The deal coincides with Genome Medical's closing of a $60 million Series C financing led by Casdin Capital to accelerate commercial growth and expand technology-enabled genetic services.

Swiss Rockets AG Acquires Complete Genomics

February 23, 2026

Healthcare Services

Complete Genomics, a U.S.-based genomic sequencing technology company, entered into a definitive agreement to be acquired by Switzerland-based life sciences group Swiss Rockets AG. The deal is expected to scale Complete Genomics’ innovation pipeline and expand/diversify manufacturing capacity, while maintaining continuity for customers and Complete Genomics’ U.S.-based operations and software support.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

Genetic Technologies Acquires AffinityDNA Direct-to-Consumer Business

July 14, 2022

Biotechnology

Genetic Technologies Limited (GENE) completed the acquisition of the direct-to-consumer eCommerce business and distribution rights of AffinityDNA, including websites, brand identities, laboratory testing and distribution agreements. The deal expands GENE’s direct-to-consumer channel and product portfolio across the US, UK and Europe, adding AffinityDNA’s consumer and pet genomics offerings to GENE’s geneType and EasyDNA brands.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Ampersand Capital Partners Completes Growth Equity Investment in GenDx

May 8, 2019

Biotechnology

Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.